The MHLW has approved AstraZeneca's sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin 5mg and 10mg tablets), as a once-daily oral treatment for type 2 diabetes. The application was submitted to the MHLW by Bristol-Myers Squibb….
written on 24.03.2014
AZ's Forxiga and Taiho's Lonsurf get Japanese approval
